Initial Triple Combination Therapy Including Intravenous Prostaglandin I<sub>2</sub> for the Treatment of Patients with Severe Pulmonary Arterial Hypertension-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Initial Triple Combination Therapy Including Intravenous Prostaglandin I<sub>2</sub> for the Treatment of Patients with Severe Pulmonary Arterial Hypertension

Published:2023-07-29 Issue:4 Volume:64 Page:684-692
ISSN:1349-2365
Container-title:International Heart Journal
language:en
Short-container-title:Int. Heart J.

Author:

Tamura Yuichi¹,Kumamaru Hiraku¹,Nishimura Shiori²,Nakajima Yasuo³,Matsubara Hiromi¹,Taniguchi Yu⁴,Tsujino Ichizo¹,Shigeta Ayako¹,Kinugawa Koichiro¹,Kimura Kazuhiro¹,Tatsumi Koichiro⁵

Affiliation:

1. Japan Pulmonary Hypertension Registry (JAPHR) Network

2. Department of Healthcare Quality Assessment, Graduate School of Medicine, The University of Tokyo

3. Medical Division, GSK K.K.

4. Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine

5. Department of Respirology, Graduate School of Medicine, Chiba University

Publisher

International Heart Journal (Japanese Heart Journal)

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/ihj/64/4/64_23-047/_pdf

Reference27 articles.

1. 1. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J 2022; 43: 3618-731.

2. 2. Hoeper MM, McLaughlin VV, Dalaan AM, Satoh T, Galiè N. Treatment of pulmonary hypertension. Lancet Respir Med 2016; 4: 323-36.

3. 3. Takahashi Y, Yamamoto K, Tanabe N, et al. Characteristics of Japanese elderly patients with pulmonary arterial hypertension. Pulm Circ 2020; 10: 2045894020954158.

4. 4. Lang IM, Gaine SP. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. Eur Respir Rev 2015; 24: 630-41.

5. 5. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142: 448-56.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study);Pharmaceuticals;2024-04-26

2. Case report: Extracorporeal life support as a successful bridge to recovery in an incident case of pulmonary arterial hypertension;Frontiers in Medicine;2024-02-06

3. Reducing the pressure in pulmonary arterial hypertension: sotatercept, haemodynamics and the right ventricle;European Respiratory Journal;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3